This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses ...

Two key advances in the 1980s — genome sequencing and structure-based drug design ... Importantly, for HCV, combination of antiviral drugs with immunomodulatory interferons may eradicate ...

Using their model, they've built a detailed picture of Nsp2—not just as a single rigid structure ... tools that help design antiviral drugs as efficiently as possible could save countless ...

It has insufficient stores of antiviral medications, leaving the country vulnerable to the next great disease outbreak. Vaccines are often seen as the primary means of preventing the spread of ...

An alternative to Paxlovid, the only antiviral pills approved by the US Food and Drug Administration to treat COVID-19, is on the horizon. Pfizer—the maker of Paxlovid—has begun Phase 3 ...

Many antiviral drugs work by inhibiting viral RNA polymerase ... However, without a clear understanding of the Nipah virus ...

Antiviral drugs can be used for the treatment of influenza and the prevention of seasonal and post-exposure influenza. Four antiviral drugs are available for the prevention and treatment of ...

Cocrystal Pharma (NASDAQ:COCP – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March 27th. Analysts expect Cocrystal Pharma to post earnings of ($0.55) ...